IL-2 induces transient arrest in the G1 phase to protect cervical cancer cells from entering apoptosis

14Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Interleukin 2 (IL-2) has been used for the treatment of different types of cancer that express the IL-2 receptor (IL-2R). However, the effect of IL-2 on cervical cancer cells is unknown. IL-2R is present in normal cells of the immune system but not in the healthy cervix. We report that IL-2R is expressed in cervical cancer cells. IL-2 decreases cervical cancer cell proliferation via transient arrest of the G1 phase, which does not result in apoptosis or senescence. IL-2 upregulates the expression of p53 and p21 and downregulates cyclin D. In addition, we report the resistance of cervical cancer cells to treatments that induce apoptosis in HeLa and INBL cells. When arrested cells were treated with cisplatin, the cytokine protected cells from apoptosis induced by cisplatin. The effects of IL-2 on the cell cycle do not induce cellular senescence or activate the proapoptotic protein Bax. The cell arrest induced by IL-2 is conferring protection to cells against apoptosis.

Cite

CITATION STYLE

APA

Lagunas-Cruz, M. D. C., Valle-Mendiola, A., Trejo-Huerta, J., Rocha-Zavaleta, L., Mora-García, M. D. L., Gutiérrez-Hoya, A., … Soto-Cruz, I. (2019). IL-2 induces transient arrest in the G1 phase to protect cervical cancer cells from entering apoptosis. Journal of Oncology, 2019. https://doi.org/10.1155/2019/7475295

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free